These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Goodman GR; Burian C; Koziol JA; Saven A J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Rosenberg JD; Burian C; Waalen J; Saven A Blood; 2014 Jan; 123(2):177-83. PubMed ID: 24192579 [TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889 [TBL] [Abstract][Full Text] [Related]
5. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Dearden CE; Matutes E; Hilditch BL; Swansbury GJ; Catovsky D Br J Haematol; 1999 Aug; 106(2):515-9. PubMed ID: 10460614 [TBL] [Abstract][Full Text] [Related]
7. My treatment approach to hairy cell leukemia. Naik RR; Saven A Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049 [TBL] [Abstract][Full Text] [Related]
9. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756 [TBL] [Abstract][Full Text] [Related]
11. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328 [TBL] [Abstract][Full Text] [Related]
12. [Hairy cell leukemia treated with cladribine]. Ghanima W; Heldal D; Tjønnfjord GE Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051 [TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Nieva J; Bethel K; Saven A Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446 [TBL] [Abstract][Full Text] [Related]
14. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. Hoffman MA; Janson D; Rose E; Rai KR J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556 [TBL] [Abstract][Full Text] [Related]
15. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Huynh E; Sigal D; Saven A Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692 [TBL] [Abstract][Full Text] [Related]
16. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Piro LD; Ellison DJ; Saven A Leuk Lymphoma; 1994; 14 Suppl 1():121-5. PubMed ID: 7820043 [TBL] [Abstract][Full Text] [Related]
17. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with hairy cell leukemia in the south of Iran. Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461 [TBL] [Abstract][Full Text] [Related]
19. The optimal management of hairy cell leukaemia. Gollard R; Lee TC; Piro LD; Saven A Drugs; 1995 Jun; 49(6):921-31. PubMed ID: 7543840 [TBL] [Abstract][Full Text] [Related]